Peer-reviewedCC BYNPJ precision oncology
The promise and limits of patient-reported outcomes in molecular tumor board-guided care: toward a framework for patient-centered precision oncology.
14 affiliations
- 1Department of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
- 2Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- 3Medical Informatics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- 4Institute for Medical Informatics and Biometry, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.
- 5Charité - Universitätsmedizin Berlin, Berlin Institute of Health @ Charité, Berlin, Germany.
- 6Center for Patient-Centered Outcomes Research, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Charité Platz 1, Berlin, Germany.
- 7Department of Psychosomatic Medicine, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Berlin, Germany.
- 8Medical Center for Information and Communication Technology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- 9SRH Fürth University of Applied Sciences, Fürth, Germany.
- 10Data Integration Center, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg im Breisgau, Freiburg, Germany.
- 11Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
- 12Department I of Internal Medicine, Center for Integrated Oncology Cologne, University Hospital Cologne, Cologne, Germany.
- 13Institute for Medical Informatics and Biometry, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany. [email protected].
- 14Center for Scalable Data Analytics and Artificial Intelligence (ScaDS.AI Dresden/Leipzig), Dresden, Saxony, Germany. [email protected].
Abstract
Patient-reported outcomes (PROs) capture symptoms, functioning, quality of life, treatment burden and priorities directly from patients. Their integration into Molecular Tumor Board (MTB)-guided care remains limited and particularly challenging, as recommendations often involve off-label therapies, sparse evidence and complex benefit-burden trade-offs. In this perspective, we propose a four-domain framework encompassing measurement, data integration, decision support and governance to guide longitudinal monitoring and patient-centered learning.
Related
- Patient-Reported Outcomes After Aptos Thread-Centered Treatment in Real-World Aesthetic Practice
- Integrating Real-World Evidence, Patient-Reported Outcomes and Health Economics into Evidence-Based Public Health-A Narrative Review and Conceptual Framework.
- Precision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification
- The maturation of precision medicine into pragmatic, patient-centered care: A commentary on the 2026 EHA CLL Guidelines.
- Shared Decision-Making and Decision Support in Advanced Chronic Kidney Disease: A Systematic Review of Models, Treatment Pathways, and Patient-Centered Outcomes
BibTeX
@article{graßel2026promise,
title = {{The promise and limits of patient-reported outcomes in molecular tumor board-guided care: toward a framework for patient-centered precision oncology.}},
author = {L Gräßel and S Yacob and C Strantz and E Prochaska and T Debertshäuser and A A Rogge and S Bäcker and F Prasser and P Unberath and J Wehrle and S Jäger and M Boerries and A L Illert and U Lührig and M Wolfien},
journal = {NPJ precision oncology},
year = {2026},
month = oct,
doi = {10.1038/s41698-026-01719-0},
url = {https://europepmc.org/article/MED/42963351},
note = {CC BY},
}
RIS
TY - JOUR
TI - The promise and limits of patient-reported outcomes in molecular tumor board-guided care: toward a framework for patient-centered precision oncology.
AU - L Gräßel
AU - S Yacob
AU - C Strantz
AU - E Prochaska
AU - T Debertshäuser
AU - A A Rogge
AU - S Bäcker
AU - F Prasser
AU - P Unberath
AU - J Wehrle
AU - S Jäger
AU - M Boerries
AU - A L Illert
AU - U Lührig
AU - M Wolfien
PY - 2026
DA - 2026/10/29
JO - NPJ precision oncology
DO - 10.1038/s41698-026-01719-0
UR - https://europepmc.org/article/MED/42963351
AB - Patient-reported outcomes (PROs) capture symptoms, functioning, quality of life, treatment burden and priorities directly from patients. Their integration into Molecular Tumor Board (MTB)-guided care remains limited and particularly challenging, as recommendations often involve off-label therapies, sparse evidence and complex benefit-burden trade-offs. In this perspective, we propose a four-domain framework encompassing measurement, data integration, decision support and governance to guide longitudinal monitoring and patient-centered learning.
SN - 2397-768X
ER -